Cumulative disease damage and anti-PM/Scl antibodies are associated with a heavy burden of calcinosis in systemic sclerosis.
SSc
anti-PM/Scl
calcinosis
Journal
Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501
Informations de publication
Date de publication:
02 11 2023
02 11 2023
Historique:
received:
20
05
2022
accepted:
27
11
2022
medline:
9
11
2023
pubmed:
6
12
2022
entrez:
5
12
2022
Statut:
ppublish
Résumé
Ectopic calcification (calcinosis) is a common complication of SSc, but a subset of SSc patients has a heavy burden of calcinosis. We examined whether there are unique risk factors for a heavy burden of calcinosis, as compared with a light burden or no calcinosis. We reviewed the medical records of all patients in the Johns Hopkins Scleroderma Center Research Registry with calcinosis to quantify calcinosis burden using pre-specified definitions. We performed latent class analysis to identify SSc phenotypic classes. We used multinomial logistic regression to determine whether latent phenotypic classes and autoantibodies were independent risk factors for calcinosis burden. Of all patients, 29.4% (997/3388) had calcinosis, and 13.5% (130/963) of those with calcinosis had a heavy burden. The latent phenotypic class with predominantly diffuse skin disease and higher disease severity (characterized by pulmonary hypertension, interstitial lung disease, cardiomyopathy, severe RP, gastrointestinal involvement, renal crisis, myopathy and/or tendon friction rubs) was associated with an increased risk of both a heavy burden [odds ratio (OR) 6.92, 95% CI 3.66, 13.08; P < 0.001] and a light burden (OR 2.88, 95% CI 2.11, 3.95; P < 0.001) of calcinosis compared with the phenotypic class with predominantly limited skin disease. Autoantibodies to PM/Scl were strongly associated with a heavy burden of calcinosis (OR 17.31, 95% CI 7.72, 38.81; P < 0.001) and to a lesser degree a light burden of calcinosis (OR 3.59, 95% CI 1.84, 7.00; P < 0.001). Calcinosis burden is associated with cumulative SSc-related tissue damage. Independent of disease severity, autoantibodies to PM/Scl are also associated with a heavy burden of calcinosis.
Identifiants
pubmed: 36469337
pii: 6873735
doi: 10.1093/rheumatology/keac682
pmc: PMC10629791
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
3636-3643Subventions
Organisme : NIAMS NIH HHS
ID : P30 AR070254
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR073208
Pays : United States
Organisme : NIAMS NIH HHS
ID : T32 AR048522
Pays : United States
Organisme : NIAMS NIH HHS
ID : K24 AR080217
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Int J Rheum Dis. 2021 Jun;24(6):803-808
pubmed: 33909342
Autoimmunity. 2015;48(8):542-51
pubmed: 26334795
Arthritis Rheum. 2008 Dec;58(12):3902-12
pubmed: 19035499
J Natl Cancer Inst. 1993 Feb 3;85(3):230-5
pubmed: 8423628
Arthritis Rheumatol. 2015 Dec;67(12):3234-44
pubmed: 26246178
Clin Rheumatol. 2017 Jan;36(1):111-117
pubmed: 27718018
Scand J Rheumatol. 2016;45(2):114-7
pubmed: 26448593
J Rheumatol. 1983 Apr;10(2):242-6
pubmed: 6864678
Scand J Rheumatol. 2017 Mar;46(2):118-121
pubmed: 27682520
Arthritis Care Res (Hoboken). 2021 Sep;73(9):1332-1337
pubmed: 32475057
Mod Rheumatol. 2018 May;28(3):518-522
pubmed: 28722530
Arthritis Rheumatol. 2014 Jun;66(6):1608-15
pubmed: 24577935
Am J Respir Crit Care Med. 2008 Jun 1;177(11):1248-54
pubmed: 18369202
Ann Rheum Dis. 2014 Jun;73(6):1060-6
pubmed: 23606705
Arthritis Care Res (Hoboken). 2018 Jun;70(6):938-943
pubmed: 28898558
J Rheumatol. 1999 Oct;26(10):2159-67
pubmed: 10529133
Mod Rheumatol. 2021 Nov;31(6):1113-1119
pubmed: 33566708
Semin Arthritis Rheum. 2016 Dec;46(3):344-349
pubmed: 27371996
Hum Pathol. 2006 Feb;37(2):190-7
pubmed: 16426919
Arthritis Rheum. 1992 Oct;35(10):1211-7
pubmed: 1418007
Rheumatology (Oxford). 2021 Nov 3;60(11):5028-5041
pubmed: 33580257
Arthritis Res Ther. 2003;5(2):80-93
pubmed: 12718748
Arthritis Rheumatol. 2019 Sep;71(9):1553-1570
pubmed: 30969034
Rheumatology (Oxford). 2021 Feb 1;60(2):849-854
pubmed: 32829395
Semin Arthritis Rheum. 2018 Dec;48(3):482-494
pubmed: 29602558
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
Arthritis Rheum. 1980 May;23(5):581-90
pubmed: 7378088
Arthritis Rheumatol. 2020 Mar;72(3):465-476
pubmed: 31682743
Arthritis Care Res (Hoboken). 2016 Mar;68(3):366-73
pubmed: 26223810
Semin Arthritis Rheum. 2020 Oct;50(5):891-896
pubmed: 32898758
Clin Exp Rheumatol. 2017 Mar-Apr;35(2):303-308
pubmed: 27908312
Rheumatology (Oxford). 2004 Apr;43(4):461-6
pubmed: 15024134